公开(公告)号：EP1285930A2

公开(公告)日：2003-02-26

申请号：EP02022788.0

申请日：1997-02-10

申请人： BASF AKTIENGESELLSCHAFT

发明人： Salfeld, Jochen G. ,  Allen, Deborah J. ,  Hoogenboom, Hendricus R.J.M. ,  Kaymakcalan, Zehra ,  Labkovsky, Boris ,  Mankovich, John A. ,  McGuinness, Brian T. ,  Roberts, Andrew J. ,  Sakorafas, Paul ,  Schoenhaut, David ,  Vaughan, Tristan J. ,  White, Michael ,  Wilton, Alison J.

IPC分类号： C07K16/24 ,  C12N15/09 ,  A61K39/395

CPC分类号： C07K16/241 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  Y02A50/412 ,  Y10S424/80 ,  Y10S424/81 ,  Y10S530/868

摘要： Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα ( e.g ., K d = 10 -8 M or less), a slow off rate for hTNFα dissociation ( e.g ., K off = 10 -3 sec -1 or less) and neutralize hTNFα activity in vitro and in vivo . An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

摘要翻译： 公开了特异性结合人肿瘤坏死因子±（hTNF±）的人抗体，优选重组人抗体。 这些抗体对hTNF±（例如，K d = 10 -8 M或更小）具有高亲和力，hTNF±解离（例如，K off = 10 -3 sec -1或更低）的缓慢率，并中和hTNF 体外和体内的±活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 本发明的抗体或抗体部分可用于检测hTNF±和抑制hTNF±活性，例如， 在患有hTNF±活性有害的病症的人类受试者中。 用于表达本发明的重组人抗体的核酸，载体和宿主细胞以及合成重组人抗体的方法也包括在本发明中。